News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alzheimer's Drug: It May be Too Late for Pfizer Inc. (PFE), Johnson & Johnson (JNJ) to Try



9/18/2012 7:01:20 AM

When Pfizer and J&J announced that their Alzheimer’s drug, bapineuzumab (bapi), had failed to impact this disease in a major clinical trial, there was disappointment. Surprisingly, there was also a fair degree of criticism that these companies had taken the risk of running late stage studies with bapi. The reason for this criticism was that the mid-stage clinical trials with bapi gave equivocal results and plunging into phase 3 was highly risky. Given the phase 3 outcome, the naysayers felt that their concerns were validated.

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES